InvestorsObserver is giving Immunitybio Inc (IBRX) an Analyst Rating Rank of 36, meaning IBRX is ranked higher by analysts than 36% of stocks. The average price target for IBRX is $4.5 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating IBRX a Buy today. Find out what this means to you and get the rest of the rankings on IBRX!
You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.
InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.
What's Happening With Immunitybio Inc Stock Today?
Immunitybio Inc (IBRX) stock is trading at $4.05 as of 11:23 AM on Wednesday, Nov 29, an increase of $0.01, or 0.25% from the previous closing price of $4.04. The stock has traded between $4.02 and $4.28 so far today. Volume today is low. So far 1,265,431 shares have traded compared to average volume of 8,564,379 shares.
Click Here to get the full Stock Report for Immunitybio Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter